S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NASDAQ:ATRA - Atara Biotherapeutics Stock Price, Forecast & News

$15.70
+0.82 (+5.51 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$14.85
Now: $15.70
$15.86
50-Day Range
$10.55
MA: $13.31
$15.67
52-Week Range
$10.38
Now: $15.70
$43.58
Volume1.20 million shs
Average Volume668,664 shs
Market Capitalization$850.17 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATRA
CUSIPN/A
Phone650-278-8930

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.42 per share

Profitability

Net Income$-230,700,000.00

Miscellaneous

Employees321
Market Cap$850.17 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter.


Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics Inc (NASDAQ:ATRA) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($1.31) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.40) by $0.09. View Atara Biotherapeutics' Earnings History.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Atara Biotherapeutics.

What price target have analysts set for ATRA?

11 equities research analysts have issued 12-month price targets for Atara Biotherapeutics' stock. Their forecasts range from $9.00 to $70.00. On average, they expect Atara Biotherapeutics' stock price to reach $29.88 in the next twelve months. This suggests a possible upside of 90.3% from the stock's current price. View Analyst Price Targets for Atara Biotherapeutics.

What is the consensus analysts' recommendation for Atara Biotherapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Atara Biotherapeutics.

What are Wall Street analysts saying about Atara Biotherapeutics stock?

Here are some recent quotes from research analysts about Atara Biotherapeutics stock:
  • 1. According to Zacks Investment Research, "Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. " (11/12/2019)
  • 2. William Blair analysts commented, "We view the results as very promising given the high efficacy and very favorable safety profile, with no evidence of on-target, off-tumor toxicity of the CAR-T therapy . Given the strong expression of mesothelin across several tumor types, including mesothelioma (90%-plus), lung adenocarcinoma (60%-plus), triple negative breast cancer (TNBC, 35%), and pancreatic cancer (80%), the opportunity for a mesothelin- CAR-T therapy with a strong safety profile is significant." (4/1/2019)
  • 3. Mizuho analysts commented, "We note that this is not the first time the company has put an ATM in place." (2/26/2019)

Has Atara Biotherapeutics been receiving favorable news coverage?

Media coverage about ATRA stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Atara Biotherapeutics earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Atara Biotherapeutics.

Are investors shorting Atara Biotherapeutics?

Atara Biotherapeutics saw a increase in short interest in November. As of November 29th, there was short interest totalling 10,440,000 shares, an increase of 5.2% from the November 14th total of 9,920,000 shares. Based on an average trading volume of 691,500 shares, the days-to-cover ratio is currently 15.1 days. Currently, 21.8% of the shares of the company are short sold. View Atara Biotherapeutics' Current Options Chain.

Who are some of Atara Biotherapeutics' key competitors?

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include Crispr Therapeutics (CRSP), Editas Medicine (EDIT), AbbVie (ABBV), Micron Technology (MU), Exelixis (EXEL), Portola Pharmaceuticals (PTLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Amgen (AMGN) and AT&T (T).

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the folowing people:
  • Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)
  • Mr. Utpal Koppikar, Chief Financial Officer (Age 49)
  • Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)
  • Ms. Mina Kim, Sr. VP of Corp. Strategy, Gen. Counsel & Sec. (Age 45)
  • Dr. Dietmar P. Berger M.D., Ph.D., Global Head of R&D (Age 56)

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Maverick Capital Ltd. (9.43%), Redmile Group LLC (8.35%), State Street Corp (4.81%), Eagle Asset Management Inc. (3.04%), Great Point Partners LLC (0.92%) and Alberta Investment Management Corp (0.67%). Company insiders that own Atara Biotherapeutics stock include Carol Giltner Gallagher, Christopher Haqq, Derrell Porter, Eric Dobmeier, Heather D Turner, Isaac E Ciechanover, Joe Newell, Joel S Marcus, John Mcgrath, Matthew K Fust, Mitchall G Clark and Utpal Koppikar. View Institutional Ownership Trends for Atara Biotherapeutics.

Which major investors are selling Atara Biotherapeutics stock?

ATRA stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC and Barclays PLC. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Christopher Haqq, Derrell Porter, Isaac E Ciechanover, Joe Newell and Joel S Marcus. View Insider Buying and Selling for Atara Biotherapeutics.

Which major investors are buying Atara Biotherapeutics stock?

ATRA stock was acquired by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Great Point Partners LLC, State Street Corp, Coronation Fund Managers Ltd., Alberta Investment Management Corp, Russell Investments Group Ltd., Trellus Management Company LLC and Eagle Asset Management Inc.. Company insiders that have bought Atara Biotherapeutics stock in the last two years include Eric Dobmeier and Utpal Koppikar. View Insider Buying and Selling for Atara Biotherapeutics.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $15.70.

How big of a company is Atara Biotherapeutics?

Atara Biotherapeutics has a market capitalization of $850.17 million. The biotechnology company earns $-230,700,000.00 in net income (profit) each year or ($5.27) on an earnings per share basis. Atara Biotherapeutics employs 321 workers across the globe.View Additional Information About Atara Biotherapeutics.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is http://www.atarabio.com/.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.


MarketBeat Community Rating for Atara Biotherapeutics (NASDAQ ATRA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  374 (Vote Outperform)
Underperform Votes:  287 (Vote Underperform)
Total Votes:  661
MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote "Outperform" if you believe ATRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: S&P/ASX 200 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel